Literature DB >> 34839537

Revision of the Australian guidelines to reduce health risks from drinking alcohol.

Katherine M Conigrave1,2, Robert L Ali3, Rebecca Armstrong4, Tanya N Chikritzhs5,6, Peter d'Abbs6, Mark F Harris7, Nicole Hewlett6,8, Michael Livingston5, Dan I Lubman9,10, Anne McKenzie11, Colleen O'Leary12, Alison Ritter13, Scott Wilson2,14, Melanie Grimmond15, Emily Banks16.   

Abstract

INTRODUCTION: The Australian guidelines to reduce health risks from drinking alcohol were released in 2020 by the National Health and Medical Research Council. Based on the latest evidence, the guidelines provide advice on how to keep the risk of harm from alcohol low. They refer to an Australian standard drink (10 g ethanol). RECOMMENDATIONS: •Guideline 1: To reduce the risk of harm from alcohol-related disease or injury, healthy men and women should drink no more than ten standard drinks a week and no more than four standard drinks on any one day. The less you drink, the lower your risk of harm from alcohol. •Guideline 2: To reduce the risk of injury and other harms to health, children and people under 18 years of age should not drink alcohol. •Guideline 3: To prevent harm from alcohol to their unborn child, women who are pregnant or planning a pregnancy should not drink alcohol. For women who are breastfeeding, not drinking alcohol is safest for their baby. CHANGES AS RESULT OF THE GUIDELINE: The recommended limit for healthy adults changed from two standard drinks per day (effectively 14 per week) to ten per week. The new guideline states that the less you drink, the lower your risk of harm from alcohol. The recommended maximum on any one day remains four drinks (clarified from previously "per drinking occasion"). Guidance is clearer for pregnancy and breastfeeding, and for people aged less than 18 years, recommending not drinking.
© 2021 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

Entities:  

Keywords:  Alcohol-related disorders; Health communication; Policy, drugs and alcohol; Prevention and control; Preventive medicine

Mesh:

Year:  2021        PMID: 34839537      PMCID: PMC9299166          DOI: 10.5694/mja2.51336

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   12.776


The National Health and Medical Research Council (NHMRC) of Australia is responsible for developing guidelines on a wide range of public, clinical and environmental health issues. Since 1987 this has included guidelines on reducing the health risks of alcohol, with the latest revision released in 2020.

Drinking and harm in Australia

Alcohol contributes 4.5% of the burden of disease and injury in Australia and is the lead contributor at age 15–44 years. The pattern of drinking influences harms. For example, consuming 14 standard drinks on a single day increases the risk of acute harms, such as injury and heart rhythm problems, far more than drinking two drinks daily over a week. Both patterns are likely to increase risks of chronic conditions, such as cancer, compared with not drinking. In Australia, the commonest frequency of consumption is 3 days per week.

Rationale for revising the guidelines on alcohol consumption

Evidence on alcohol and health has evolved considerably since the last update of the NHMRC guidelines in 2009. Evidence linking alcohol to cancer risk has strengthened, particularly at lower levels of consumption. Alcohol is classed as a Group 1 carcinogen by the International Agency for Research on Cancer, with strong evidence of increased risk of seven types of cancer: breast, colon and rectum, pancreas, liver, oesophagus, mouth, and throat and pharynx. Most of these cancers demonstrate increasing risk on a continuum of growing alcohol consumption. For example, the risk of breast cancer in women increases by 12% per additional standard drink (10 g ethanol) per day, with elevated risks apparent from an average of one standard drink per day. Consistent with this changing evidence, internationally recommended limits to reduce risk from alcohol consumption have been decreasing steadily, including recent downward revisions in the United Kingdom, the Netherlands and France. There is also increasing uncertainty over the extent and veracity of reported protective effects of alcohol against a range of health conditions, including myocardial infarction. Rigorous analysis, limited to cohorts with well defined comparison groups, shows far less, if any, protective effect. Similarly, Mendelian randomisation studies have also cast doubt over purported protective effects.

Creating guidelines for a risk that is voluntarily taken

Tight guidelines are typically placed on environmental (involuntary) toxins to keep the risk of dying from that cause at no more than around one in 1 million. However, individuals typically choose to drink alcohol, despite some awareness of the risk. The 2009 guidelines to reduce health risks from drinking alcohol for the general adult population used drinking thresholds that would limit lifetime (absolute) risk of dying from an alcohol‐related cause to less than one in 100 — similar to the lifetime level of risk of driving a car (data from the United States). This is very different from choosing the guideline that minimises the risk of alcohol‐related harm, which would give a far lower limit. A guideline that eliminates risks from alcohol altogether would advise no consumption. In this article, we describe the process of revising the Australian guidelines to reduce health risks from drinking alcohol and the resulting guidelines.

Methods

Overview of the guidelines revision process

The revision of the guidelines followed standard NHMRC processes, which are similar to the Appraisal of Guidelines for Research and Evaluation (AGREE) II criteria. , Key stages of the revision process were: Establishing an independent expert advisory committee, comprising 14 members with expertise in epidemiology, sociology, medicine, mental health, addiction, public health, and community engagement. Procuring systematic reviews and mathematical modelling to provide evidence on short and long term harms and benefits associated with various levels and patterns of drinking; the population, exposure, comparator and outcome (PECO) criteria and protocols were determined in advance by the committee. Applying the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) process to rate quality and certainty of the evidence; the GRADE Evidence to Decision frameworks were used to translate evidence into recommendations and provide transparency around decision making. Undertaking public consultation to understand issues of concern for the public and stakeholders and to ensure accountability of the agency, independence of the guidelines, and an improved final guideline. Obtaining independent expert reviews of the protocols, systematic reviews, guidelines and mathematical modelling; this helped ensure the guidelines followed the rigorous approach specified in the research protocols, assessed certainty of the evidence on which the recommendations were based and usability and acceptability of recommendations. Endorsement of the guidelines by the Council of the NHMRC, whose members include state, territory and Commonwealth chief health and medical officers.

The evidence base for the guidelines

Multiple sources of evidence were considered by the committee (Box 1). This included: Source: National Health and Medical Research Council. the 2009 guidelines; international guidance on reducing risks from drinking alcohol; evidence reviews on the health effects of alcohol; data on health indicators, alcohol consumption and other features of the Australian community; and mathematical modelling. The process also drew upon the expertise of the NHMRC Alcohol Working Committee, and took into account public health and implementation considerations and best practice guideline development approaches.

The 2009 guidelines

The committee started with the principle that the 2009 guidelines should only be changed if there was compelling evidence of need to do so. For the guideline for the general adult population, the committee retained the aim to ascertain the upper level of drinking that would limit lifetime (absolute) risk of dying from an alcohol‐related cause to less than one in 100.

International guidelines

There is considerable variation in guidelines internationally and, as described above, the recommended drinking limits have been reducing. France and the United Kingdom currently recommend drinking no more than the equivalent of ten to 11 Australian standard drinks over a week respectively, while the Netherlands recommends zero or not more than seven per week.

The evidence review

An overview of systematic reviews was conducted to consider the short and long term health risks and benefits associated with various levels and patterns of drinking alcohol. This focused on identifying systematic reviews and meta‐analyses published since 2007 to identify areas where evidence has grown since the 2009 guidelines. Research protocols were first reviewed by the Committee. These outlined the scope; scientific question, including PECO; the search strategy; and methods. Over 50 health outcomes were selected by the Committee as highly relevant for determining the guidelines. Importance to the public of a health outcome was considered in the selection (Box 2). All‐cause mortality Bladder cancer Brain cancer Breast cancer (premenopausal) Breast cancer (postmenopausal) Cervical cancer Colorectal cancer Endometrial cancer Gallbladder cancer Kidney cancer Liver cancer Lung cancer Hodgkin lymphoma Non‐Hodgkin lymphoma Leukaemia Multiple myeloma Melanoma Mouth and pharynx cancer Larynx cancer Oesophageal squamous cell carcinoma Oesophageal adenocarcinoma Ovarian cancer Pancreatic cancer Prostate cancer Stomach cancer Thyroid cancer Coronary heart disease Atrial fibrillation Heart failure Ischaemic stroke Intracerebral haemorrhage Subarachnoid haemorrhage Hypertension Liver cirrhosis Pancreatitis Type 2 diabetes Dementia and cognitive decline Seizures Hip fracture Gout Pneumonia Tuberculosis Injury Fatal motor vehicle injury Myocardial infarction or coronary event Ischaemic stroke Haemorrhagic stroke Depression/depressive symptoms Anxiety/anxiety symptoms Bipolar disorder Suicide/suicide ideation/suicide attempts PTSD/PTSD symptoms Cognition Preterm birth Small for gestational age Communication delay Behavioural problems Low birthweight Child motor function Birth defects Sedation PTSD = post‐traumatic stress disorder. The systematic reviews focused on the physical and psychological health harms of alcohol use to the individual drinking and to the developing fetuses and babies of mothers who consume alcohol while pregnant or breastfeeding. The reviews did not include social or economic outcomes, despite the Committee acknowledging these harms can be substantial. It was noted that if an individual’s consumption is kept to the recommended guidelines, this would also be likely to reduce the risk of social and economic harms from alcohol. The overviews of systematic reviews were commissioned from external researchers. Additional systematic reviews were also commissioned if no quality systematic reviews were located, especially if the topic was of high importance. In total, 38 high quality systematic reviews were selected and four additional systematic reviews were commissioned on mental health, long term cognitive impairment, pregnancy and breastfeeding. The quality and certainty of the evidence was evaluated using the GRADE approach, with modifications for public health studies as described elsewhere. Other tools were also used to assess the systematic reviews: A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) and the Risk of Bias in Systematic Reviews (ROBIS).

The nature and quality of the evidence

The quality of the evidence included in the systematic reviews varied across outcomes. GRADE rates the type of epidemiological evidence typical of broad public health exposures as low to very low; accordingly, the certainty in the overall evidence was rated as very low. More highly rated study designs that are considered necessary for clinical practice guidelines, such as randomised control trials, are not appropriate for most public health exposures. This is chiefly because randomisation to many public health exposures of interest, such as smoking, alcohol, or early age at first pregnancy, is often either impractical or unethical. Well designed observational studies are often the best source of evidence on public health issues. The available evidence had several limitations. Well known associations (eg, between alcohol and cirrhosis) were often observed in older research, when standards of documentation of methods were different. Also, very heavy drinkers are typically under‐represented in cohorts. Reverse causation can complicate interpretation of findings; for example, people who have become sick or have developed a problem with alcohol may reduce their alcohol consumption. There is also limited evidence on the impacts of lower levels of consumption among youth and on the effects of alcohol on children whose mothers drink alcohol while breastfeeding.

Public call for evidence

The NHMRC made an early public call for evidence submissions on health risks and benefits of alcohol consumption to complement the systematic reviews, mathematical modelling, and other evidence considered. This call helped identify relevant studies and gaps in the evidence, as well as areas of concern for stakeholders. Clear inclusion and exclusion criteria ensured that only studies of reasonable quality were accepted. As the additional literature was collected outside the systematic review process, it could not be evaluated using the GRADE approach applied to the systematic reviews. Instead, the evidence from the public call was considered along with evidence from the 2009 guidelines, systematic reviews, modelling and other evidence and contributed to the narrative text for the guidelines.

Additional articles

Additional articles of particular significance were also considered; for example, if they were published after the last systematic review. A transparent process was implemented for choosing and assessing the quality of additional articles. These articles included Mendelian randomisation studies, recent major cohort studies, experimental studies, and imaging studies on brain development among youth. Such articles could not be incorporated as core inputs into the guideline development, but they could be used in explanation and as an influencer when decisions were not clearly based on other sources of evidence.

Mathematical modelling

The mathematical model developed by the School of Health and Related Research at the University of Sheffield was adapted for Australian alcohol consumption and health data. The model derives the absolute risk of dying from disease or injury related to alcohol for different patterns and levels of drinking. Australian data on drinking patterns and alcohol‐related morbidity and mortality were used as inputs. The consumption threshold, which corresponds to a one in 100 risk of dying from an alcohol‐related cause, was examined. The committee used the absolute risk of dying from an alcohol‐related cause rather than the relative risk (ie, rather than how many times greater or lower the risk of dying is at different levels of alcohol consumption). Because current abstainers can differ from drinkers in a range of ways that are likely to bias results, they were not used as a comparison group. Current non‐drinkers, for example, can include past drinkers who stopped drinking as a result of an illness.

Principles for considering the body of evidence

The Committee agreed the following a priori regarding the modelling evidence on alcohol‐related mortality: To consider the typical pattern of drinking in Australia when setting guidelines for healthy (non‐pregnant/non‐breastfeeding) adults. Accordingly, the drinking frequency of 3 days per week was used. To round down rather than up when deciding on limits, given the growing uncertainty over the cardioprotective effects of alcohol, the ongoing emergence of research showing that the risk of common cancers increases from low levels of consumption, and the need for caution (eg, a limit of 12.5 from the modelling would be considered a limit of 12). To provide a guideline that is easy to implement. There was little difference between the lifetime risk of alcohol‐related death in males compared with females at lower levels of consumption (between zero and ten standard drinks per week). Among individuals who drink 3 days per week, the risk of dying from an alcohol‐related cause becomes one in 100 at just over ten standard drinks per week for both men and women. Therefore, there was no compelling reason to change from the approach of the 2009 guidelines, which had the same limit for men and women in the general population. The committee agreed to use the precautionary principle in relation to pregnancy and breastfeeding, and for those under the age of 18 years, because of evidence of potential major harms to the developing brain from alcohol. To develop the guidelines, the committee also applied the GRADE Evidence to Decision frameworks. As part of this process, the committee considered the quality and certainty of the evidence, the values and preferences of the target population, the impact of the recommendation on health equity, the resource implications, and the feasibility and acceptability of the recommendation and other considerations.

Public consultation and independent expert review

Public consultation is a core feature of the NHMRC’s guideline development, contributing to accountability of the agency and independence of the advice. The draft guidelines were released for a 10‐week public consultation in December 2019. The process was conducted in accordance with Section 13 of the National Health and Medical Research Council Act 1992. The online publication of the draft guidelines was accompanied by a media release and the consultation was advertised through the NHMRC website, the NHMRC newsletter, and social media. Correspondence was also sent to a large number of stakeholders inviting them to provide input. In total, 49 public consultation submissions were received. All were considered. No errors of fact or significant omissions of evidence were identified, but phrasing of the guidelines and accompanying resources were clarified at several points. After revisions in response to public consultation, the guidelines underwent review by four independent experts. The modelling was also reviewed independently by a team of six experts. After feedback from the expert review, the guidelines were further refined. The final guidelines were released in December 2020 following endorsement by the NHMRC Council.

Recommendations

After taking into consideration all the sources of evidence, public feedback and expert review, the Committee devised the following guidelines to reduce the risk from alcohol consumption.

Guideline 1: adults

To reduce the risk of harm from alcohol‐related disease or injury, healthy men and women should drink no more than ten standard drinks a week and no more than four standard drinks on any one day. The less you drink, the lower your risk of harm from alcohol.

Guideline 2: children and people under 18 years of age

To reduce the risk of injury and other harms to health, children and people under 18 years of age should not drink alcohol.

Guideline 3: women who are pregnant or breastfeeding

To prevent harm from alcohol to their unborn child, women who are pregnant or planning a pregnancy should not drink alcohol. For women who are breastfeeding, not drinking alcohol is safest for their baby. The guidelines are summarised in Box 3, with examples of standard drinks given in Box 4. Source: National Health and Medical Research Council. Source: National Health and Medical Research Council. The key differences from the previous guidelines are that: the guidelines for short and long term harm were combined into a single guideline; the total weekly recommended consumption limit was effectively changed from 14 standard drinks to ten; and the recommended drinking limit for any one day remained the same (at four drinks) but was clarified (it was previously phrased as “per drinking occasion”). The statement “the less you drink, the lower your risk of harm from alcohol” was added to clarify that any level of drinking can convey some risk of harm. Furthermore, individuals with health conditions are again advised to seek medical advice on drinking. For pregnancy, breastfeeding and people aged under 18 years, the guidance not to drink alcohol was made clearer. The publication of the guidelines was accompanied by press releases and considerable media coverage. The full guidelines are available online at https://www.nhmrc.gov.au/about‐us/publications/australian‐guidelines‐reduce‐health‐risks‐drinking‐alcohol, and are also published on MAGICApp at https://app.magicapp.org/#/guideline/4630. The Commonwealth Department of Health is responsible for the implementation of the guidelines.

Competing interests

Until December 2020, Michael Livingston was deputy director of the Centre for Alcohol Policy Research at La Trobe University, which received core funding from the Foundation for Alcohol Research and Education (FARE), a not‐for‐profit organisation working towards an Australia free from alcohol harms.

Provenance

Not commissioned; externally peer reviewed.
Health conditions
Long term health conditions

All‐cause mortality

Bladder cancer

Brain cancer

Breast cancer (premenopausal)

Breast cancer (postmenopausal)

Cervical cancer

Colorectal cancer

Endometrial cancer

Gallbladder cancer

Kidney cancer

Liver cancer

Lung cancer

Hodgkin lymphoma

Non‐Hodgkin lymphoma

Leukaemia

Multiple myeloma

Melanoma

Mouth and pharynx cancer

Larynx cancer

Oesophageal squamous cell carcinoma

Oesophageal adenocarcinoma

Ovarian cancer

Pancreatic cancer

Prostate cancer

Stomach cancer

Thyroid cancer

Coronary heart disease

Atrial fibrillation

Heart failure

Ischaemic stroke

Intracerebral haemorrhage

Subarachnoid haemorrhage

Hypertension

Liver cirrhosis

Pancreatitis

Type 2 diabetes

Dementia and cognitive decline

Seizures

Hip fracture

Gout

Pneumonia

Tuberculosis

Short term health conditions

Injury

Fatal motor vehicle injury

Myocardial infarction or coronary event

Ischaemic stroke

Haemorrhagic stroke

Mental health conditions

Depression/depressive symptoms

Anxiety/anxiety symptoms

Bipolar disorder

Suicide/suicide ideation/suicide attempts

PTSD/PTSD symptoms

Cognitive impairment conditions

Cognition

Pregnancy outcomes

Preterm birth

Small for gestational age

Communication delay

Behavioural problems

Low birthweight

Child motor function

Birth defects

Breastfeeding outcomes

Sedation

PTSD = post‐traumatic stress disorder.

  11 in total

Review 1.  AGREE II: advancing guideline development, reporting and evaluation in health care.

Authors:  Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger
Journal:  CMAJ       Date:  2010-07-05       Impact factor: 8.262

2.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.

Authors:  Pablo Alonso-Coello; Holger J Schünemann; Jenny Moberg; Romina Brignardello-Petersen; Elie A Akl; Marina Davoli; Shaun Treweek; Reem A Mustafa; Gabriel Rada; Sarah Rosenbaum; Angela Morelli; Gordon H Guyatt; Andrew D Oxman
Journal:  BMJ       Date:  2016-06-28

3.  Alcohol Consumption and Mortality From Coronary Heart Disease: An Updated Meta-Analysis of Cohort Studies.

Authors:  Jinhui Zhao; Tim Stockwell; Audra Roemer; Timothy Naimi; Tanya Chikritzhs
Journal:  J Stud Alcohol Drugs       Date:  2017-05       Impact factor: 2.582

4.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

5.  Moderate alcohol intake and cancer incidence in women.

Authors:  Naomi E Allen; Valerie Beral; Delphine Casabonne; Sau Wan Kan; Gillian K Reeves; Anna Brown; Jane Green
Journal:  J Natl Cancer Inst       Date:  2009-02-24       Impact factor: 13.506

6.  Towards a framework for evaluating and grading evidence in public health.

Authors:  Thomas Harder; Muna Abu Sin; Xavier Bosch-Capblanch; Helena de Carvalho Gomes; Phillippe Duclos; Tim Eckmanns; Randy Elder; Simon Ellis; Frode Forland; Paul Garner; Roberta James; Andreas Jansen; Gérard Krause; Daniel Lévy-Bruhl; Antony Morgan; Joerg J Meerpohl; Susan Norris; Eva Rehfuess; Alex Sánchez-Vivar; Holger Schünemann; Anja Takla; Ole Wichmann; Walter Zingg; Teun Zuiderent-Jerak
Journal:  Health Policy       Date:  2015-03-23       Impact factor: 2.980

7.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

Authors:  Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter
Journal:  BMC Med Res Methodol       Date:  2007-02-15       Impact factor: 4.615

8.  Why does society accept a higher risk for alcohol than for other voluntary or involuntary risks?

Authors:  Jürgen Rehm; Dirk W Lachenmeier; Robin Room
Journal:  BMC Med       Date:  2014-10-21       Impact factor: 8.775

9.  Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.

Authors:  Iona Y Millwood; Robin G Walters; Xue W Mei; Yu Guo; Ling Yang; Zheng Bian; Derrick A Bennett; Yiping Chen; Caixia Dong; Ruying Hu; Gang Zhou; Bo Yu; Weifang Jia; Sarah Parish; Robert Clarke; George Davey Smith; Rory Collins; Michael V Holmes; Liming Li; Richard Peto; Zhengming Chen
Journal:  Lancet       Date:  2019-04-04       Impact factor: 202.731

10.  Developing policy analytics for public health strategy and decisions-the Sheffield alcohol policy model framework.

Authors:  Alan Brennan; Petra Meier; Robin Purshouse; Rachid Rafia; Yang Meng; Daniel Hill-Macmanus
Journal:  Ann Oper Res       Date:  2013-10-08       Impact factor: 4.854

View more
  2 in total

1.  The aetiology and clinical characteristics of cryptococcal infections in Far North Queensland, tropical Australia.

Authors:  Beatrice Z Sim; Luke Conway; Laura K Smith; Lee Fairhead; Yi Shan Der; Lara Payne; Enzo Binotto; Simon Smith; Josh Hanson
Journal:  PLoS One       Date:  2022-03-30       Impact factor: 3.240

2.  The impact of COVID-19 on nurse alcohol consumption: A qualitative exploration.

Authors:  Adam Searby; Dianna Burr; Bernice Redley
Journal:  J Clin Nurs       Date:  2022-07-24       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.